WAVE Life Sciences Stock

WAVE Life Sciences EBIT 2024

WAVE Life Sciences EBIT

-147.36 M USD

Ticker

WVE

ISIN

SG9999014716

WKN

A1436W

In 2024, WAVE Life Sciences's EBIT was -147.36 M USD, a 116.71% increase from the -68 M USD EBIT recorded in the previous year.

The WAVE Life Sciences EBIT history

YEAREBIT (undefined USD)
2029e-
2028e30.95
2027e-41.58
2026e-156.08
2025e-154.08
2024e-147.36
2023-68
2022-162.72
2021-127.02
2020-153.38
2019-208.32
2018-159.52
2017-102.39
2016-55.72
2015-19.3
2014-5.39
2013-3.57

WAVE Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into WAVE Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by WAVE Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects WAVE Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of WAVE Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into WAVE Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing WAVE Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on WAVE Life Sciences’s growth potential.

WAVE Life Sciences Revenue, EBIT and net profit per share

DateWAVE Life Sciences RevenueWAVE Life Sciences EBITWAVE Life Sciences Net Income
2029e519.25 M undefined0 undefined147.64 M undefined
2028e323.49 M undefined30.95 M undefined31.18 M undefined
2027e210.15 M undefined-41.58 M undefined-27.94 M undefined
2026e97.42 M undefined-156.08 M undefined-138.23 M undefined
2025e66.66 M undefined-154.08 M undefined-156.93 M undefined
2024e70.53 M undefined-147.36 M undefined-156.51 M undefined
2023113.31 M undefined-68 M undefined-57.51 M undefined
20223.65 M undefined-162.72 M undefined-161.82 M undefined
202140.96 M undefined-127.02 M undefined-122.25 M undefined
202020.08 M undefined-153.38 M undefined-149.91 M undefined
201915.98 M undefined-208.32 M undefined-193.64 M undefined
201814.41 M undefined-159.52 M undefined-146.65 M undefined
20173.89 M undefined-102.39 M undefined-101.98 M undefined
20161.09 M undefined-55.72 M undefined-55.66 M undefined
2015150,000 undefined-19.3 M undefined-19.2 M undefined
20140 undefined-5.39 M undefined-5.23 M undefined
20130 undefined-3.57 M undefined-3.32 M undefined

WAVE Life Sciences stock margins

The WAVE Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of WAVE Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for WAVE Life Sciences.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the WAVE Life Sciences's sales revenue. A higher gross margin percentage indicates that the WAVE Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the WAVE Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the WAVE Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the WAVE Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the WAVE Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the WAVE Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

WAVE Life Sciences Margin History

WAVE Life Sciences Gross marginWAVE Life Sciences Profit marginWAVE Life Sciences EBIT marginWAVE Life Sciences Profit margin
2029e0 %0 %28.43 %
2028e0 %9.57 %9.64 %
2027e0 %-19.79 %-13.3 %
2026e0 %-160.23 %-141.9 %
2025e0 %-231.13 %-235.4 %
2024e0 %-208.93 %-221.91 %
20230 %-60.01 %-50.76 %
20220 %-4,458.08 %-4,433.42 %
20210 %-310.11 %-298.46 %
20200 %-763.84 %-746.56 %
20190 %-1,303.63 %-1,211.76 %
20180 %-1,107.01 %-1,017.7 %
20170 %-2,632.13 %-2,621.59 %
20160 %-5,111.93 %-5,106.42 %
20150 %-12,866.67 %-12,800 %
20140 %0 %0 %
20130 %0 %0 %

WAVE Life Sciences Aktienanalyse

What does WAVE Life Sciences do?

WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing WAVE Life Sciences's EBIT

WAVE Life Sciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of WAVE Life Sciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

WAVE Life Sciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in WAVE Life Sciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about WAVE Life Sciences stock

How much did WAVE Life Sciences achieve in EBIT for the current year?

In the current year, WAVE Life Sciences has achieved an EBIT of -147.36 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company WAVE Life Sciences.

How has the EBIT of WAVE Life Sciences developed in recent years?

The EBIT of WAVE Life Sciences has increased by 116.715% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company WAVE Life Sciences?

The EBIT of WAVE Life Sciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does WAVE Life Sciences pay?

Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of WAVE Life Sciences?

The current dividend yield of WAVE Life Sciences is .

When does WAVE Life Sciences pay dividends?

WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WAVE Life Sciences?

WAVE Life Sciences paid dividends every year for the past 0 years.

What is the dividend of WAVE Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is WAVE Life Sciences located?

WAVE Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WAVE Life Sciences from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did WAVE Life Sciences pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of WAVE Life Sciences in the year 2023?

In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.

In which currency does WAVE Life Sciences pay out the dividend?

The dividends of WAVE Life Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von WAVE Life Sciences

Our stock analysis for WAVE Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of WAVE Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.